Sugi Predict

Sugi Predict / Compounds / SCHEMBL2416099

SCHEMBL2416099

SCHEMBL2416099

CC(C)(Sc1nc(CCOc2ccc(-c3ccc(Cl)cc3)nn2)cs1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 4/20 0.40
▸ SLC22A12 Q96S37 3/20 0.39
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ TP53 P04637 5/20 0.35
▸ MAPT P10636 3/20 0.35
▸ LTB4R Q15722 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2410859 0.92 PPARA (0.39) PPARASLC22A12LTB4RMEN1KMT2A
SCHEMBL2412721 0.92 RAB9A (0.42) PPARASLC22A12NPC1RAB9AL3MBTL1
SCHEMBL2410471 0.91 SLC22A12 (0.41) PPARASLC22A12NPC1RAB9AMEN1
SCHEMBL2418574 0.90 ABL1 (0.38) PPARASLC22A12NPC1RAB9ATP53
SCHEMBL2409355 0.89 SLC22A12 (0.40) PPARASLC22A12NPC1RAB9AL3MBTL1
SCHEMBL2412316 0.88 SHMT2 (0.37) PPARASLC22A12NPC1RAB9AALDH1A1
SCHEMBL2415696 0.88 PPARA (0.42) PPARANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL2415490 0.87 PPARA (0.41) PPARASLC22A12LTB4R
SCHEMBL2415482 0.87 SLC22A12 (0.40) PPARASLC22A12TDP1TP53MAPT
SCHEMBL12271748 0.85 SLC22A12 (0.41) PPARASLC22A12NPC1RAB9ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PPARA 1/4885SLC22A12 920/4885NPC1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.